Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PLAAT5 | Q96KN8 | 4/20 | 0.31 |
| ▸ | PLAAT4 | Q9UL19 | 4/20 | 0.31 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.31 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452602 | 0.85 | CA12 (0.53) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14428358 | 0.82 | CA12 (0.46) | CA12CA1CA2CA9NPSR1 | |
| SCHEMBL5462110 | 0.82 | CA12 (0.47) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL25074809 | 0.79 | CA12 (0.51) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14428357 | 0.79 | CA12 (0.57) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5450873 | 0.79 | CA12 (0.43) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL6370201 | 0.79 | CA12 (0.56) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL5455408 | 0.78 | CA12 (0.49) | CA12CA1CA2CA9 | |
| SCHEMBL5469439 | 0.78 | CA12 (0.40) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5450923 | 0.78 | IDO1 (0.46) | ALDH1A1MAPTHPGDIDO1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CA12 1186/4885CA1 661/4885CA2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.